Darrel Francis speaks to Faiez Zannad about his meta-analysis of SGLT2 inhibitors for heart failure with reduced ejection fraction published in The Lancet. This interview takes you through the key components of the meta-analysis: Forest plots, what to make of the heterogeneity of effect, and subgroup analyses. Should we believe in subgroup analysis? Is there mechanistic plausibility? Is there any value in meta-analysing only two trials?

For more debate, join the CVCT Forum 2020 session on Saturday, December 5th: Understanding the Results of SGLT2 Inhibitors Heart Failure Trials.

Register here : www.globalcvctforum.com

+ posts
+ posts

Leave a Reply